For research use only. Not for therapeutic Use.
Clovoxamine（Cat No.:I006170）is a selective serotonin reuptake inhibitor (SSRI) that has been studied primarily for its potential in treating psychiatric disorders, particularly depression and anxiety. It works by increasing serotonin levels in the brain, which helps improve mood and reduce symptoms of anxiety. Though structurally related to other SSRIs, clovoxamine has shown distinct pharmacological properties in preclinical studies, which could influence its clinical efficacy and side effect profile. However, it has not been widely marketed, and its use remains limited to research settings, with further trials needed to confirm its therapeutic potential.
| Catalog Number | I006170 |
| CAS Number | 54739-19-4 |
| Synonyms | Clovoxamine;(E)-1-(4-chlorophenyl)-5-methoxypentan-1-one O-(2-aminoethyl) oxime |
| Molecular Formula | C14H21ClN2O2 |
| Purity | ≥95% |
| Target | GPCR/G Protein |
| Solubility | Soluble in DMSO |
| Storage | -20°C |
| IUPAC Name | 2-[(E)-[1-(4-chlorophenyl)-5-methoxypentylidene]amino]oxyethanamine |
| InChI | InChI=1S/C14H21ClN2O2/c1-18-10-3-2-4-14(17-19-11-9-16)12-5-7-13(15)8-6-12/h5-8H,2-4,9-11,16H2,1H3/b17-14+ |
| InChIKey | XXPVSQRPGBUFKM-SAPNQHFASA-N |
| SMILES | COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)Cl |
| Reference | </br>1:Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients. Spring B, Gelenberg AJ, Garvin R, Thompson S.Psychopharmacology (Berl). 1992;108(3):327-32. PMID: 1523282 </br>2:Clovoxamine in the treatment of depressed outpatients: a double-blind, parallel-group comparison against amitriptyline and placebo. Gelenberg AJ, Wojcik JD, Falk WE, Spring B, Brotman AW, Galvin-Nadeau M.Compr Psychiatry. 1990 Jul-Aug;31(4):307-14. PMID: 2201481 </br>3:Anxiety neurosis in general practice. A double-blind comparative study of diazepam and clovoxamine, a novel inhibitor of noradrenaline and serotonin reuptake. Jesinger DK, Gostick N.Int Clin Psychopharmacol. 1989 Oct;4(4):301-11. PMID: 2691573 </br>4:Effect of clovoxamine fumarate on the electrocardiogram. Goldie A, Edwards JG.J Psychopharmacol. 1989 Jan;3(1):29-31. doi: 10.1177/026988118900300105. PMID: 22156308 </br>5:Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness. Ochs HR, Greenblatt DJ, Verburg-Ochs B, Labedski L.J Clin Pharmacol. 1989 Jan;29(1):91-5. PMID: 2496149 </br>6:Biochemical effects in rats after acute and long-term treatment with clovoxamine. Bradford LD, Tulp MT, Schipper J.Arch Int Pharmacodyn Ther. 1987 Jun;287(2):188-202. PMID: 2820327 </br>7:Acute comparison of clovoxamine and mianserin, alone and in combination with ethanol, on human psychomotor performance. Strömberg C, Mattila MJ.Pharmacol Toxicol. 1987 May;60(5):374-9. PMID: 3615347 </br>8:Fluorimetric determination of fluvoxamine or clovoxamine in human plasma after thin-layer chromatographic or high-performance liquid chromatographic separation. Schweitzer C, Spahn H, Mutschler E.J Chromatogr. 1986 Oct 31;382:405-11. No abstract available. PMID: 3097046 </br>9:Clovoxamine and doxepin in major depressive disorder: a double-blind controlled trial. Lodge GJ, Freeman HL.Br J Psychiatry. 1986 Jun;148:718-21. PMID: 3535975 </br>10:[Action of clovoxamine on the sleep of depressed patients. /Polygraphic recordings/]. Minot R, Crocq MA, Roussel B, Marie-Cardine M.Encephale. 1985 Mar-Apr;11(2):65-70. French. PMID: 4017939 |
